Positive opinion moves eribulin closer to approval in Japan
This article was originally published in Scrip
Executive Summary
Eisai's novel anticancer agent Halaven (eribulin mesylate) has received a positive approval recommendation in Japan for use in breast cancer, taking it a step closer to launch in what will become an important market.